Patents by Inventor James Stewart Scott
James Stewart Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220169643Abstract: The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R6, R7, R8, Linker, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.Type: ApplicationFiled: March 27, 2020Publication date: June 2, 2022Inventors: Bin YANG, Thomas George Christopher HAYHOW, Charlene FALLAN, James Stewart SCOTT, Coura Rosalie DIENE, Bernard Christophe BARLAAM, Johannes Wilhelmus Maria NISSINK
-
Publication number: 20210284636Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: February 17, 2021Publication date: September 16, 2021Inventors: Bernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
-
Patent number: 11046689Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: GrantFiled: January 29, 2020Date of Patent: June 29, 2021Assignee: AstraZeneca ABInventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
-
Patent number: 10961241Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: GrantFiled: January 28, 2020Date of Patent: March 30, 2021Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Daniel Hillebrand O'Donovan, Samantha Jayne Hughes, Thomas Andrew Moss, Johannes Wilhelmus Maria Nissink, James Stewart Scott, Bin Yang
-
Publication number: 20200239468Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: January 29, 2020Publication date: July 30, 2020Inventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
-
Publication number: 20200239467Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: January 28, 2020Publication date: July 30, 2020Inventors: Bernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
-
Patent number: 10590130Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: GrantFiled: October 9, 2018Date of Patent: March 17, 2020Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Daniel Hillebrand O'Donovan, Samantha Jayne Hughes, Thomas Andrew Moss, Johannes Wilhelmus Maria Nissink, James Stewart Scott, Bin Yang
-
Patent number: 10590132Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: GrantFiled: January 31, 2019Date of Patent: March 17, 2020Assignee: AstraZeneca ABInventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
-
Publication number: 20190233413Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: January 31, 2019Publication date: August 1, 2019Inventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
-
Publication number: 20190100520Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: October 9, 2018Publication date: April 4, 2019Inventors: Bernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
-
Patent number: 10221173Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: GrantFiled: January 29, 2018Date of Patent: March 5, 2019Assignee: AstraZeneca ABInventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
-
Patent number: 10149839Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: July 24, 2017Date of Patent: December 11, 2018Assignee: AstraZeneca ABInventors: James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam, Dan Anders Broo, Bin Yang, Jeffrey Gilbert Varnes, Dedong Wu
-
Patent number: 10131663Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: GrantFiled: October 13, 2017Date of Patent: November 20, 2018Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Daniel Hillebrand O'Donovan, Samantha Jayne Hughes, Thomas Andrew Moss, Johannes Wilhelmus Maria Nissink, James Stewart Scott, Bin Yang
-
Patent number: 10125135Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: April 19, 2017Date of Patent: November 13, 2018Assignee: AstraZeneca ABInventors: Bin Yang, Jeffrey Gilbert Varnes, James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam
-
Publication number: 20180282325Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: January 29, 2018Publication date: October 4, 2018Inventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
-
Publication number: 20180111931Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: October 13, 2017Publication date: April 26, 2018Inventors: Bernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
-
Publication number: 20180021316Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: July 24, 2017Publication date: January 25, 2018Inventors: James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam, Dan Anders Broo, Bin Yang, Jeffrey Gilbert Varnes, Dedong Wu
-
Publication number: 20170305909Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: April 19, 2017Publication date: October 26, 2017Inventors: Bin YANG, Jeffrey Gilbert VARNES, James Stewart SCOTT, Thomas Andrew MOSS, Daniel Hillebrand O'DONOVAN, Johannes Wilhelmus Maria NISSINK, Samantha Jayne HUGHES, Bernard Christophe BARLAAM
-
Patent number: 8673938Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.Type: GrantFiled: August 14, 2009Date of Patent: March 18, 2014Assignee: AstraZeneca ABInventors: William McCoull, Martin Packer, James Stewart Scott, Paul Robert Owen Whittamore
-
Patent number: 8344016Abstract: A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are also described.Type: GrantFiled: September 9, 2010Date of Patent: January 1, 2013Assignee: AstraZeneca ABInventors: Martin John Packer, James Stewart Scott, Andrew Stocker, Paul Robert Owen Whittamore